Traverse Biotech II Inc
Publicly observedNew York, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | New York | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Traverse Biotech II Inc | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | JJUSGRQS7RM5 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Sept 2026Publicly observed
NIH SBIR/STTR award: Development of a uPAR-Targeting Antibody-Drug Conjugate (ADC) for Pancreatic Adenocarcinoma
USD 399,896.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 May 2024Publicly observed
NIH SBIR/STTR award: Orally available NOD2 agonist, HPX-612, for the treatment of visceral leishmaniasis
USD 297,717.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.